Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
出版年份 2021 全文链接
标题
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
作者
关键词
-
出版物
Nature Reviews Nephrology
Volume 18, Issue 1, Pages 56-70
出版商
Springer Science and Business Media LLC
发表日期
2021-10-21
DOI
10.1038/s41581-021-00490-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
- (2021) Takayuki Yamada et al. Cardiovascular Diabetology
- Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
- (2021) Yaru Zhang et al. CARDIOVASCULAR DRUGS AND THERAPY
- Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
- (2021) Li Shen et al. JACC-Heart Failure
- Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
- (2021) Stefan J Schunk et al. EUROPEAN HEART JOURNAL
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
- (2021) João Pedro Ferreira et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Quadruple Medical Therapy for Heart Failure
- (2021) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data
- (2021) Niti Mittal et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel mineralocorticoid receptor mechanisms regulate cardiac tissue inflammation in male mice
- (2020) Gregory S.y Ong et al. JOURNAL OF ENDOCRINOLOGY
- Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes
- (2020) Skander Mulder et al. Translational Research
- Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post‐discharge
- (2020) Patrick Rossignol et al. ESC Heart Failure
- Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease
- (2020) George Bakris et al. HYPERTENSION
- Evolution of Patiromer Use: a Review
- (2020) Waleed Ali et al. Current Cardiology Reports
- Aldosterone, Inflammation, Immune System, and Hypertension
- (2020) Nathanne S Ferreira et al. AMERICAN JOURNAL OF HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
- (2020) Niels H. Brandt-Jacobsen et al. DIABETES & METABOLISM
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy
- (2020) Mostafa El Mokadem et al. CardioRenal Medicine
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
- (2020) Stefan D. Anker et al. CIRCULATION
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
- (2019) Dan Dong et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity
- (2019) Clara Lefranc et al. HYPERTENSION
- Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
- (2019) Hillel Sternlicht et al. CURRENT HYPERTENSION REPORTS
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Diet-Induced Obesity Promotes Kidney Endothelial Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor
- (2019) Annayya R. Aroor et al. HYPERTENSION
- Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation
- (2019) Patricio Araos et al. JOURNAL OF HYPERTENSION
- The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward
- (2019) Patrick Rossignol et al. KIDNEY INTERNATIONAL
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- The effects of dapagliflozin on systemic and renal vascular function display an epigenetic signature
- (2019) Anna Solini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cutaneous wound healing in diabetic mice is improved by topical mineralocorticoid receptor blockade
- (2019) Van Tuan Nguyen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
- (2019) Hiromi Rakugi et al. HYPERTENSION RESEARCH
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
- (2019) Kitty J. Jager et al. KIDNEY INTERNATIONAL
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Rajiv Agarwal et al. LANCET
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The single-cell transcriptomic landscape of early human diabetic nephropathy
- (2019) Parker C. Wilson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Vascular mineralocorticoid receptor activation and disease
- (2019) Jonatan Barrera-Chimal et al. EXPERIMENTAL EYE RESEARCH
- Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2019) Catherine M. Clase et al. KIDNEY INTERNATIONAL
- NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus
- (2019) Nathanne Santos Ferreira et al. Cells
- Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors
- (2018) Matthew R. Weir et al. AMERICAN JOURNAL OF MEDICINE
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation
- (2018) Mathieu Buonafine et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
- (2018) Benjamin Bonnard et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- OUP accepted manuscript
- (2018) NEPHROLOGY DIALYSIS TRANSPLANTATION
- Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature
- (2018) Scott M. Brown et al. PHARMACOLOGICAL RESEARCH
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Eplerenone Reverses Cardiac Fibrosis via the Suppression of Tregs by Inhibition of Kv1.3 Channel
- (2018) Pei-Pei Shao et al. Frontiers in Physiology
- MicroRNA-21 Ablation Exacerbates Aldosterone-Mediated Cardiac Injury, Remodeling and Dysfunction
- (2018) Maryam Syed et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Vascular dysfunction in obese diabetic db/db mice involves the interplay between aldosterone/mineralocorticoid receptor and Rho kinase signaling
- (2018) Aurelie Nguyen Dinh Cat et al. Scientific Reports
- Comparative Analysis and Refinement of Human PSC-Derived Kidney Organoid Differentiation with Single-Cell Transcriptomics
- (2018) Haojia Wu et al. Cell Stem Cell
- Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing
- (2018) Daniela Fraccarollo et al. HYPERTENSION
- RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition
- (2018) Sandor Koszegi et al. JOURNAL OF PHYSIOLOGY-LONDON
- Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis
- (2018) Haojia Wu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
- (2018) Chen-Ta Yang et al. Journal of Clinical Medicine
- Mineralocorticoid Receptor Deficiency in T Cells Attenuates Pressure Overload–Induced Cardiac Hypertrophy and Dysfunction Through Modulating T-Cell ActivationNovelty and Significance
- (2017) Chao Li et al. HYPERTENSION
- A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
- (2017) Shigehiro Katayama et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron
- (2017) Shigeru Shibata JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature
- (2017) Jennifer J DuPont et al. JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Deletion of the Mineralocorticoid Receptor in Myeloid Cells Attenuates Central Nervous System Autoimmunity
- (2017) Elena Montes-Cobos et al. Frontiers in Immunology
- The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis
- (2016) Kevin Quach et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Mineralocorticoid Receptor Deficiency in Macrophages Inhibits Neointimal Hyperplasia and Suppresses Macrophage Inflammation Through SGK1-AP1/NF-κB PathwaysSignificance
- (2016) Jian-Yong Sun et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages
- (2016) Jimmy Z. Shen et al. ENDOCRINOLOGY
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune and vascular dysfunction in diabetic wound healing
- (2016) A.S. Ahmed et al. Journal of Wound Care
- Macrophage depletion lowers blood pressure and restores sympathetic nerve α2-adrenergic receptor function in mesenteric arteries of DOCA-salt hypertensive rats
- (2015) Loc V. Thang et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Impairment of Wound Healing in Patients With Type 2 Diabetes Mellitus Influences Circulating MicroRNA Patterns via Inflammatory Cytokines
- (2015) S. Dangwal et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Nonsteroidal antagonists of the mineralocorticoid receptor
- (2015) Peter Kolkhof et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions
- (2015) ZHUO LI et al. Molecular Medicine Reports
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epithelial Sodium Transport and Its Control by Aldosterone: The Story of Our Internal Environment Revisited
- (2015) Bernard C. Rossier et al. PHYSIOLOGICAL REVIEWS
- Collecting Duct Principal Cell Transport Processes and Their Regulation
- (2014) D. Pearce et al. Clinical Journal of the American Society of Nephrology
- Chronic kidney disease and cardiovascular complications
- (2014) Luca Di Lullo et al. HEART FAILURE REVIEWS
- Spironolactone Decreases DOCA–Salt–Induced Organ Damage by Blocking the Activation of T Helper 17 and the Downregulation of Regulatory T Lymphocytes
- (2014) Cristián A. Amador et al. HYPERTENSION
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
- (2014) L. L. Huang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Local Mineralocorticoid Receptor Activation and the Role of Rac1 in Obesity-Related Diabetic Kidney Disease
- (2014) Shigetaka Yoshida et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease
- (2014) Ivana Lazich et al. SEMINARS IN NEPHROLOGY
- Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy
- (2013) Thomas A. Mavrakanas et al. European Journal of Internal Medicine
- Deficiency of the Interleukin 17/23 Axis Accelerates Renal Injury in Mice With Deoxycorticosterone Acetate+Angiotensin II–Induced Hypertension
- (2013) Christian F. Krebs et al. HYPERTENSION
- Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway
- (2013) Dan Zhu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aldosterone Antagonists in Monotherapy Are Protective against Streptozotocin-Induced Diabetic Nephropathy in Rats
- (2012) Nora F. Banki et al. PLoS One
- Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
- (2011) D. K. Packham et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Pirfenidone for Diabetic Nephropathy
- (2011) K. Sharma et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat
- (2011) Bruno S Pessôa et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Oxidation of CaMKII determines the cardiotoxic effects of aldosterone
- (2011) B Julie He et al. NATURE MEDICINE
- Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease
- (2011) M. Lian et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production
- (2011) J. Toyonaga et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice
- (2010) Michael G. Usher et al. JOURNAL OF CLINICAL INVESTIGATION
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Aldosterone: effects on the kidney and cardiovascular system
- (2010) Marie Briet et al. Nature Reviews Nephrology
- Myeloid-Specific Deletion of the Mineralocorticoid Receptor Reduces Infarct Volume and Alters Inflammation During Cerebral Ischemia
- (2010) Ryan A. Frieler et al. STROKE
- Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade
- (2009) Nitin Khosla et al. AMERICAN JOURNAL OF NEPHROLOGY
- Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure
- (2009) Amanda J. Rickard et al. HYPERTENSION
- Aldosterone Promotes Autoimmune Damage by Enhancing Th17-Mediated Immunity
- (2009) Andrés A. Herrada et al. JOURNAL OF IMMUNOLOGY
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
- (2009) U. F. Mehdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats
- (2008) Masateru Taira et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats
- (2008) Y. S. Kang et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More